

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	LTR Pharma Limited
ABN	42 103 087 449

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lee Rodne
Date of last notice	9 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	19 November 2025
No. of securities held prior to change	<u>Direct</u> 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at \$0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at \$2.52 per option expiring 2 December 2028 <u>Indirect</u> 46,373,750 Fully Paid Ordinary Shares held by LTR Medical Pty Ltd 982,143 Fully Paid Ordinary Shares held by LTR Consulting Pty Ltd 4,188,000 Fully Paid Ordinary Shares held by Trexapharm Inc

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	Unlisted Options
Number acquired	2,000,000
Number disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration
No. of securities held after change	<u>Direct</u> 1,129,641 Fully Paid Ordinary Shares 1,000,000 Unlisted Options exercisable at \$0.22 per option expiring 31 October 2028 100,000 Unlisted Options exercisable at \$2.52 per option expiring 2 December 2028 2,000,000 Unlisted Options exercisable at \$0.5075 per option expiring 24 October 2029 <u>Indirect</u> 46,373,750 Fully Paid Ordinary Shares held by LTR Medical Pty Ltd 982,143 Fully Paid Ordinary Shares held by LTR Consulting Pty Ltd 4,188,000 Fully Paid Ordinary Shares held by Trexapharm Inc
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of 2,000,000 Unlisted Options under the Employee Incentive Plan as approved by shareholders at the Company's 2025 Annual General Meeting (Resolution 7)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.